Literature DB >> 16420244

Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function.

Maria L Wei1.   

Abstract

The Hermansky-Pudlak syndrome (HPS) is a collection of related autosomal recessive disorders which are genetically heterogeneous. There are eight human HPS subtypes, characterized by oculocutaneous albinism and platelet storage disease; prolonged bleeding, congenital neutropenia, pulmonary fibrosis, and granulomatous colitis can also occur. HPS is caused primarily by defects in intracellular protein trafficking that result in the dysfunction of intracellular organelles known as lysosome-related organelles. HPS gene products are all ubiquitously expressed and all associate in various multi-protein complexes, yet HPS has cell type-specific disease expression. Impairment of specialized secretory cells such as melanocytes, platelets, lung alveolar type II epithelial cells and cytotoxic T cells are observed in HPS. This review summarizes recent molecular, biochemical and cell biological analyses together with clinical studies that have led to the correlation of molecular pathology with clinical manifestations and led to insights into such diverse disease processes such as albinism, fibrosis, hemorrhage, and congenital neutropenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16420244     DOI: 10.1111/j.1600-0749.2005.00289.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  137 in total

1.  Modeling disease mutations by gene targeting in one-cell mouse embryos.

Authors:  Melanie Meyer; Oskar Ortiz; Martin Hrabé de Angelis; Wolfgang Wurst; Ralf Kühn
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-01       Impact factor: 11.205

2.  Hermansky-Pudlak syndrome: the importance of molecular subtyping.

Authors:  N Thielen; M Huizing; J G Krabbe; J G White; T J Jansen; P A Merle; W A Gahl; S Zweegman
Journal:  J Thromb Haemost       Date:  2010-04-30       Impact factor: 5.824

Review 3.  Cell biology of the BLOC-1 complex subunit dysbindin, a schizophrenia susceptibility gene.

Authors:  Ariana P Mullin; Avanti Gokhale; Jennifer Larimore; Victor Faundez
Journal:  Mol Neurobiol       Date:  2011-04-26       Impact factor: 5.590

4.  BLOC-2, AP-3, and AP-1 proteins function in concert with Rab38 and Rab32 proteins to mediate protein trafficking to lysosome-related organelles.

Authors:  Jarred J Bultema; Andrea L Ambrosio; Carolyn L Burek; Santiago M Di Pietro
Journal:  J Biol Chem       Date:  2012-04-16       Impact factor: 5.157

Review 5.  Mechanisms of protein delivery to melanosomes in pigment cells.

Authors:  Anand Sitaram; Michael S Marks
Journal:  Physiology (Bethesda)       Date:  2012-04

6.  Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis.

Authors:  Kevin O'Brien; James Troendle; Bernadette R Gochuico; Thomas C Markello; Jose Salas; Hilda Cardona; Jianhua Yao; Isa Bernardini; Richard Hess; William A Gahl
Journal:  Mol Genet Metab       Date:  2011-03-21       Impact factor: 4.797

7.  Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization.

Authors:  Yukihiko Iizuka; Yoshitatsu Sei; Daniel R Weinberger; Richard E Straub
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

Review 8.  Pulmonary Fibrosis in Hermansky-Pudlak Syndrome.

Authors:  Glenn W Vicary; Yeidyly Vergne; Alberto Santiago-Cornier; Lisa R Young; Jesse Roman
Journal:  Ann Am Thorac Soc       Date:  2016-10

9.  A homolog of the human Hermansky-Pudluck syndrome-5 (HPS5) gene is responsible for the oa larval translucent mutants in the silkworm, Bombyx mori.

Authors:  T Fujii; Y Banno; H Abe; S Katsuma; T Shimada
Journal:  Genetica       Date:  2012-12-19       Impact factor: 1.082

10.  Modeling neural crest induction, melanocyte specification, and disease-related pigmentation defects in hESCs and patient-specific iPSCs.

Authors:  Yvonne Mica; Gabsang Lee; Stuart M Chambers; Mark J Tomishima; Lorenz Studer
Journal:  Cell Rep       Date:  2013-04-11       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.